FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to obstetrics and gynaecology, and can be used to predict the risk of developing chronic placental insufficiency at 16-18 weeks of pregnancy in women with circulating antiphospholipid antibodies (APA) and burdened obstetric history. Performing measuring the level of D-dimer in the blood of patients at 16-18 weeks, measuring the level of antithrombin III (AT III) in the blood of pregnant women at 16-18 weeks. Also included are the values of the obtained measurements of the level of soluble fms-like tyrosine kinase (sFlt) determined in the blood of patients at 6-8 weeks and the values of the obtained measurements of the level of placental growth factor (PlGF) determined in the blood of the pregnant women at 6-8 weeks. Risk of developing chronic placental insufficiency is calculated as a percentage by the following formula: P = 1 / (1 + ez) × 100%; z = -10.152 – 0.006XD-dimer + 0.127XAT III – 0.012XsFlt/PlGF; where P is the probability of developing chronic placental insufficiency; z is the regression equation; e is the base of natural logarithms; XD-dimer is the level of D-dimer (ng/ml), determined in blood of patients at 16-18 weeks of pregnancy; XAT III is level of AT III (%), determined in blood of patients at 16-18 weeks of pregnancy; XsFlt/PlGF is the sFlt/PlGF ratio determined in the blood of patients at 6-8 weeks of pregnancy. If P is equal to 32.2% and more, a high risk of developing chronic placental insufficiency is predicted. If P is equal to 32.1% or less, a low risk of developing chronic placental insufficiency is predicted.
EFFECT: method provides the possibility of increasing the specificity and accuracy of predicting the risk of developing chronic placental insufficiency in women with circulating APA and a burdened obstetric history at 16-18 weeks of pregnancy by measuring the level of D-dimer and antithrombin III in the blood of patients at 16-18 weeks of pregnancy and measuring the level of soluble fms-like tyrosine kinase sFlt and placental growth factor P1GF in the blood of patients at 6-8 weeks.
1 cl, 2 dwg, 2 tbl, 3 ex
